BioInvent International announced on July 1st that it has further extended the research term under its cancer immunotherapy research collaboration and license agreement with Pfizer until the end of 2020.
In December 2016, the companies entered into the agreement for the development and commercialization of antibodies targeting tumor-associated myeloid cells discovered using BioInvent’s F.I.R.S.TTM drug discovery platform. The purpose of the research extension is to permit the companies to further identify and characterize new targets and antibodies binding to these targets.
In 2019 Pfizer selected the first and second target under the agreement, which triggered two payments from Pfizer to BioInvent of $300,000. BioInvent may be eligible for further milestone payments from development of antibodies directed against these targets as well as from the selection of additional targets and the development of antibodies directed against those targets.
“We are pleased to extend BioInvent’s long-running agreement with Pfizer which leverages our proprietary F.I.R.S.TTM technology platform and high-quality n-CoDeR® antibody library. This extension provides Pfizer additional time to select optimal antibodies to their targets, as well as to explore more targets and corresponding antibodies. We look forward to continuing our successful collaboration with Pfizer,” says Martin Welschof, CEO of BioInvent.
Photo of Martin Welschof: BioInvent